McDonald’s CEO Chris Kempczinski has linked a surge in adult Happy Meal purchases to the booming use of GLP-1 weight-loss medications.
Kempczinski, who has led the Chicago-based fast-food giant since 2019, told the Harvard Business Review in a recent interview that the company is tracking how appetite-suppressing drugs are reshaping customer habits. Adults who once gravitated toward the chain’s signature Big Mac are increasingly opting for the smaller, toy-included meals originally designed for children.
“What everybody knows is when you go on a GLP-1, certainly your calorie consumption goes down, calorie consumption decreases, typically 700, 800 calories per day per person when they’re on a GLP-1,” Kempczinski said. “So you just play that, of course, that’s going to have an impact in the future.”
The medications, which include popular brands like Ozempic and Wegovy, work by slowing digestion and signaling fullness to the brain. The result is a dramatically reduced daily intake that Kempczinski said demands fresh thinking from the Golden Arches.
“I think what’s important, though, is when you get into that to understand how the behavior changes,” he continued. “And certainly one of the things that we see with people who go on GLP-1s is they eat more protein.”
That shift, he noted, plays to McDonald’s strengths. “There’s a need to eat more protein. That actually works really well with our menu, because our menu is very protein forward, and we’ve got the ability to continue to innovate in protein.”
The Happy Meal phenomenon emerged when Kempczinski pressed further on how portion sizes factor into the equation. “One of the interesting things is we’re seeing more adults actually buy our Happy Meals,” he shared. “Why are they buying their Happy Meals?”
The answer, he explained, comes straight from customers themselves. “Anecdotally—again, we don’t have it in broad numbers data—but anecdotally, when we ask people, some of them say, well, ‘I like the portion size on that better because I’m on a GLP-1’. So we’re thinking about, how we might evolve the menu from a portion-size standpoint.”
Health and investment analyst Susannah Streeter told Mail Online that McDonald’s faces a broader industry reckoning. “The rise of GLP-1 weight-loss drugs is creating another headwind for food companies, as growing numbers of consumers using these treatments around the world eat less – shifting towards smaller portions and healthier choices,” she said.
Streeter added a blunt assessment of the challenge ahead: “For a business built around burgers and fries, changing appetites look set to be a big challenge ahead.”
The trend marks a notable reversal for the Happy Meal, which has long served as a gateway to brand loyalty for young customers. Introduced in 1979 with circus-themed packaging, the boxed combo of entree, side, drink and toy became a cultural staple even as adult diners typically graduated to larger, more expensive menu items.
Kempczinski’s comments signal that McDonald’s may formalize smaller-portion offerings rather than simply watching adults awkwardly order from the kids’ menu. The company has previously tested adult-oriented mini-meals and value bundles, but never explicitly tied such moves to pharmaceutical trends.
The GLP-1 category has exploded in recent years, with prescriptions surging across the United States and Europe. Originally developed for Type 2 diabetes, the drugs have gained massive off-label use for weight management, creating ripple effects through grocery, restaurant and even airline industries as consumers consume less food overall.
McDonald’s has not announced specific menu changes tied to the trend, though Kempczinski emphasized the company will continue monitoring how medication-driven habits reshape demand.